Biotricity (NASDAQ:BTCY) versus West Pharmaceutical Services (NYSE:WST) Head to Head Survey

Biotricity (NASDAQ:BTCY) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Volatility & Risk

Biotricity has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.

Valuation & Earnings

This table compares Biotricity and West Pharmaceutical Services”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	1.06	-$14.09 million	($1.08)	-0.48
West Pharmaceutical Services	$2.89 billion	5.81	$492.70 million	$6.69	34.73

West Pharmaceutical Services has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biotricity and West Pharmaceutical Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
West Pharmaceutical Services	17.03%	18.60%	13.80%

Insider and Institutional Ownership

3.9% of Biotricity shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 10.1% of Biotricity shares are held by insiders. Comparatively, 0.5% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings and target prices for Biotricity and West Pharmaceutical Services, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
West Pharmaceutical Services	0	1	5	0	2.83

West Pharmaceutical Services has a consensus price target of $344.00, indicating a potential upside of 48.04%. Given West Pharmaceutical Services’ stronger consensus rating and higher possible upside, analysts clearly believe West Pharmaceutical Services is more favorable than Biotricity.

Summary

West Pharmaceutical Services beats Biotricity on 12 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.